arrow
R

Reinhard Hohlfeld

hospital universitari vall d'hebron
H指数:99
被引数:3.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term safety and efficacy of ponesimod, an oral S1P1 receptor modulator, in relapsing-remitting multiple sclerosis (RRMS): Results from randomized phase 2b core and extension studies spanning up to 13 years

富马酸非那司提(ponesimod)在复发缓解型多发性硬化(RRMS)中的长期安全性和有效性:来自为期长达13年的随机Ⅱb期CORRE和扩展研究的成果

2026-08-010
PRE
Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trial

Ponesimod作为添加治疗在活动性复发多发性硬化患者中的应用(POINT):一项III期、随机、安慰剂对照临床试验

2025-07-130
PRE
Multiple sclerosis and gut microbiota: Lachnospiraceae from the ileum of MS twins trigger MS-like disease in germfree transgenic mice-An unbiased functional study

多发性硬化与肠道微生物组:来自MS双胞胎回肠的Lachnospiraceae可触发无菌转基因小鼠的MS样疾病——一项无偏功能研究

2025-04-210
OA
Twin study identifies early immunological and metabolic dysregulation of CD8+ T cells in multiple sclerosis

双胞胎研究确定多发性硬化症中CD8 T细胞的早期免疫和代谢失调

2024-09-270
PRE
Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis (vol 219, pg 5471, 2022)
2022-10-280
OAAI
Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis

多发性硬化患者更广泛的epstein-barr病毒特异性T细胞受体库

2022-09-0143
OAAI
Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal

制定渐进式MS的全球研究战略-国际渐进式MS联盟提案

2021-12-019
OAAI
Cross-reactivity of a pathogenic autoantibody to a tumor antigen in GABAA receptor encephalitis

GABAA受体脑炎中致病性自身抗体与肿瘤抗原的交叉反应性

2021-02-2221
OA
Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity
2020-12-2949
OAAI